Association of Tirofiban With Functional Outcomes After Thrombectomy in Acute Ischemic Stroke Due to Intracranial Atherosclerotic Disease

Hongfei Sang,Dongjing Xie,Yan Tian,Raul G Nogueira,Junxiong Wu,Chen Long,Zhenxuan Tian,Zhizhou Hu,Tao Wang,Rongzong Li,Yingbing Ke,Xiurong Zhu,Daizhou Peng,Mingze Chang,Lingfei Li,Jie Ruan,Deping Wu,Wenjie Zi,Qingwu Yang,Fengli Li,Zhongming Qiu,Thanh N. Nguyen,Jeffrey L. Saver
DOI: https://doi.org/10.1212/wnl.0000000000207194
IF: 9.9
2023-03-20
Neurology
Abstract:Objective: To investigate the efficacy and safety of intravenous infusion of tirofiban before endovascular thrombectomy for patients with large vessel occlusion due to intracranial atherosclerotic disease. The secondary objective was to identify potential mediators for the clinical effect of tirofiban. Methods: Post hoc exploratory analysis of the Endovascular Treatment With versus Without Tirofiban for Patients with Large Vessel Occlusion Stroke (RESCUE BT) trial, which was a randomized, double-blinded, placebo-controlled trial at 55 centers in China from October 2018 to October 2021. Patients with occlusion of the internal carotid artery or middle cerebral artery due to intracranial atherosclerosis were included. The primary efficacy outcome was the proportion of patients achieving functional independence (defined as modified Rankin Scale 0-2) at 90 days. Binary logistic regression and causal mediation analysis were used to estimate the treatment effect of tirofiban and the potential mediators. Results: This study included 435 patients, of whom 71.5% were men. The median age was 65 (interquartile range, 56–72) years, median National Institutes of Health Stroke Scale of 14 (interquartile range, 10–19). Patients in the tirofiban group had higher rates of functional independence at 90 days than patients in the placebo group (adjusted odds ratio, 1.68; 95% confidence interval, 1.11−2.56, P = 0.02) without increased risk of mortality or symptomatic intracranial hemorrhage. Tirofiban was associated with fewer thrombectomy passes (median [interquartile range], 1 [1–2] vs 1 [1–2], P = 0.004), which was an independent predictor of functional independence. Mediation analysis showed tirofiban-reduced thrombectomy passes explained 20.0% (95% confidence interval, 4.1%–76.0%) of the effect of tirofiban on functional independence. Conclusion: In this post hoc analysis of the RESCUE BT trial, tirofiban was an effective and well-tolerated adjuvant medication of endovascular thrombectomy for patients with large vessel occlusion due to intracranial atherosclerosis. These findings need to be confirmed in future trials.
clinical neurology
What problem does this paper attempt to address?